Cancer Vaccines Market Statistics, 2027
The global cancer vaccines market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027. Cancer vaccines are medicines considered as biological response modifiers. These biological response modifiers work by stimulating the immune system of body to fight against cancer. Preventive cancer vaccines and therapeutic cancer vaccines are two types of cancer vaccines. Preventive cancer vaccines are used in healthy person to prevent cancer. Therapeutic cancer vaccines are used in cancer patients to strengthen their immune response to fight against the disease. Cancer vaccines can be administered intravenously (IV) in children as well as in adults.
Increase in number of cancer patients, rise in geriatric population, surge in patient awareness towards cancer therapy, increase in cancer vaccines usage combined with other therapies, increase in prevalence of human papilloma virus (HPV) infections, and increase in investments and government funding in development of cancer vaccines by manufacturers are the major factors that drive growth of the cancer vaccines market. In addition, technological developments in cancer vaccines, launch of novel cancer vaccines, rise in health care services and expenditure, and rise in adoption rates of preventive and therapeutic vaccines are some other factors that contribute toward growth of the market. Moreover, increase in tobacco consumption and unhealthy dietary habits are leading risk factors for the rise in number of cancer cases, which further drives growth of the cancer vaccines market. However, high cost for developing cancer vaccines and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth.
COVID-19 Impact on Cancer Vaccines Market
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Cancer vaccines manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shutdown in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply.
Cancer Vaccines Market Segmentation
The global cancer vaccines market is segmented on the basis of technology, type, indication, end user, and region. By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. By type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. By indication, it is classified into cervical cancer, prostate cancer, and others. By end user, it is divided into pediatric and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Technology
Presently, on the basis of technology, the recombinant cancer vaccines segment is the major revenue contributor, and is projected to grow significantly during the forecast period. Increase in adoption of recombinant technology, rise in utilization of recombinant vaccines, and surge in number of approved cancer vaccines developed using recombinant technology are the key factors that boost growth of the segment.
By Technology
Recombinant Cancer Vaccines segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.
By Indication
Depending on indication, the cervical cancer segment is the major shareholder in the global cancer vaccines market, owing to high prevalence of cervical cancer and increase in number of people suffering from human papilloma virus (HPV) infections. In addition, rise in geriatric population, drug development in the field of cervical cancer, and increase in patient awareness toward cervical cancer drive growth of the segment.
By Type
Preventive Cancer Vaccines segment is projected as one of the most lucrative segment.
Snapshot of Asia-Pacific Cancer Vaccines Market
Asia-Pacific presents lucrative opportunities for key players operating in the cancer vaccines market, owing to rise in adoption of cancer vaccines, increase in number of cancer patients in emerging economies, development of the R&D sector, rise in healthcare reforms, and technological advancements in cancer vaccines. Moreover, rise in demand for cancer vaccines, surge in funding from government and non-government sectors to develop novel cancer vaccines, rise in number of hospitals & diagnostic centers equipped with advanced medical facilities, and presence of high population base contributes toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the cancer vaccines market in the region.
By Region
Asia-Pacific region would exhibit the highest CAGR of 15.0% during 2019-2026.
Competitive Analysis
The key players profiled in this report include Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc (GSK), Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Group Co. Ltd. (Dendereon Corporation), UbiVac, and Vaccinogen, Inc.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the cancer vaccines market size along with the current trends and future estimations to elucidate imminent investment pockets.
- It offers cancer vaccines market analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing opportunities in the market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global cancer vaccines market growth.
Key Market Segments:
By Technology
- Dendritic Cells (DC) Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
- Viral Vector & DNA Cancer Vaccines
By Indication
- Cervical Cancer
- Prostate Cancer
- Others
By Type
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
By End User
- Pediatrics
- Adults
By Region
North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Turkey
- South Africa
- Rest of LAMEA
Cancer Vaccines Market Report Highlights
| Aspects | Details |
 By TECHNOLOGY |
|
 By TYPES |
|
 By INDICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | UbiVac, Generex Biotechnology Corporation, Advaxis Inc., Merck & Co., Inc., Immunocellular Therapeutics, Ltd, Vaccinogen, Inc., GlaxoSmithKline plc (GSK), Dynavax Technologies Corporation, Amgen Inc., SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION) |
Analyst Review
Cancer vaccines are medications that stimulate the immune system of the body to fight against disease. Moreover, it can be administered intravenously in children as well as adults.
Rise in prevalence of cancer, increase in demand for novel cancer vaccine products, rise in adoption rates of preventive and therapeutic vaccines, and rise in investments by government & private organizations for the production of cancer vaccines significantly boost growth of the cancer vaccines market. However, high cost for developing cancer vaccines and longer time required for manufacturing a single vaccine are anticipated to restrict the market growth.
North America is expected to remain dominant during the forecast period, owing to rise in cases of cancer, high unmet demand for cancer vaccines, higher healthcare awareness, presence of well-developed healthcare infrastructure, presence of trained medical professionals, and early detection of the disease, which supports the market growth. In addition, strong reimbursement policies, presence of large number of hospitals & diagnostic centers equipped with advanced healthcare systems, and strong presence of key players supplement growth of the market in the region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to rise in number of cancer affected population with rise in demand for cancer vaccines.
The total market value of Cancer Vaccines market is $4,187.62 million in 2019.
The forcast period for Cancer Vaccines market is 2020 to 2027
The market value of Cancer Vaccines market in 2020 is $3,345.07 million.
The base year is 2019 in Cancer Vaccines market
Top companies such as Merck & Co., Inc., Amgen Inc., GlaxoSmithKline plc, Dynavax Technologies, and Sanpower Group Co., Ltd. (Dendron) held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Recombinant cancer vaccines segment is the most influencing segment owing to recombinant cancer vaccines are most efficient alternative to traditional vaccines in the prevention of various human diseases, and rise in adaption due to rapid elimination of risk of active infection.
The major factor that fuels the growth of the global Cancer Vaccines market includes rise in prevalence of cancer such as breast cancer, prostate cancer, cervical, lung cancer, and others globally, and surge in investments and governmental funding in the development of cancer vaccines by manufacturers, increase in cancer usage combined with other therapies, surge in demand for cancer vaccines, rise in public awareness towards benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines.
The major factor that fuels the growth of the global Cancer Vaccines market includes rise in prevalence of cancer such as breast cancer, prostate cancer, cervical, lung cancer, and others globally, and surge in investments and governmental funding in the development of cancer vaccines by manufacturers, increase in cancer usage combined with other therapies, surge in demand for cancer vaccines, rise in public awareness towards benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 17.0%. This is due to rise in adoption of cancer vaccines treatment medication, increase in number of cancer patients, rise in demand for cancer vaccines, improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & diagnostic centers equipped with advanced medical facilities
Cancer vaccine is a type of immunotherapy that boosts the natural defense of the body by stimulating the immune system to recognize and cure cancerous cells.
Cancer vaccine is a type of immunotherapy that boosts the natural defense of the body by stimulating the immune system to recognize and cure cancerous cells.
Cancer Vaccines products are used to effectively fight against cancer disease.
Cancer Vaccines products are used to effectively fight against cancer disease.
Loading Table Of Content...
